Incyte Corporation
$114.63-$1.24 (-1.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $20.2B
- P/E
- 15.7x
- EV / EBITDA
- 9.8x
- Revenue
- $5.1B
- Net margin
- 25.0%
- ROCE
- 24.7%
Price chart
Technical chartScreen technicals →+12.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -1.7%
- 3M
- -9.9%
- 6M
- +18.1%
- 1Y
- +12.6%
- 5Y
- +77.7%
52-week range
Day change -$1.24 (-1.1%) from $116 to $115 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in INCY, bought on each weekday since 2021.
News & filings
What Incyte filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was more than a hundred times interest costs.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Read moreShow less
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Shares outstanding
- 195.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $20.2B
- P/E
- 15.7x
- P/B
- 3.9x
- EV / EBITDA
- 9.8x
- EV / Sales
- 3.3x
- P/S
- 3.9x
- 52-week high
- $129.93
- 52-week low
- $90.30
Profitability
- Operating margin
- 26.1%
- Net margin
- 25.0%
- EBITDA margin
- 34.2%
- ROE
- 24.9%
- ROCE
- 24.7%
- ROA
- 18.5%
- Asset turnover
- 0.74
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $5.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 21.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 14.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 3845.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.3B
Solvency
- Current ratio
- 3.32
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- CFO / Net profit
- 1.10
- Cash / Market cap
- 15.3%
Where the revenue went
Of every $100 of FY2025 revenue, $25 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $372.1M |
| Revenue | Gross profit | $4.8B |
| Gross profit | Operating expenses | $3.4B |
| Gross profit | Operating income | $1.3B |
| Operating income | Pretax income | $1.3B |
| Interest and other income | Pretax income | $321.7M |
| Pretax income | Tax and other | $377.8M |
| Pretax income | Net income | $1.3B |
Revenue and net profit
Revenue grew 21.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $3.4B | $340.7M |
| FY2023 | $3.7B | $597.6M |
| FY2024 | $4.2B | $32.6M |
| FY2025 | $5.1B | $1.3B |
Cash flows
FY2025: $1.4B from operations, $1.3B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $969.9M | $892.1M |
| FY2023 | $496.5M | $449.0M |
| FY2024 | $335.3M | $235.2M |
| FY2025 | $1.4B | $1.3B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $5.1B+21.2%1Y
- EBITDA
- $1.8B+331.2%1Y
- Net profit
- $1.3B+3,845.0%1Y
- Cash from operations
- $1.4B+321.5%1Y
- Free cash flow
- $1.3B+465.4%1Y
- Revenue CAGR, 3Y
- 14.8%
- Net profit CAGR, 3Y
- 55.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.1B | $1.8B | $1.3B | $1.3B | 24.9% | +21.2% | +3845.0% |
Monthly returns
Month-by-month returns of INCY across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $7.0B |
| Current assets | $5.0B |
| Non-current assets | $1.9B |
| Liabilities | $1.8B |
| Current liabilities | $1.5B |
| Non-current liabilities | $275.3M |
| Equity | $5.2B |
| Paid-in capital | $4.9B |
| Retained earnings | $213.8M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; INCY highlighted.
P/E against peers
INCY trades at 15.7x earnings against a peer median of 23.8x (a 34% discount).
Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Incyte CorporationINCYthis companyP/E ↓ discount | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| West Pharmaceutical Services, Inc.WST | $22.4B | 45.4x | 7.1x | 15.5% | 28.4x |
| Quest Diagnostics IncorporatedDGX | $21.7B | 21.9x | 3.0x | 13.8% | 12.9x |
| Labcorp Holdings Inc.LH | $21.4B | 24.4x | 2.5x | 10.2% | 13.6x |
| STERIS plcSTE | $20.7B | 26.5x | 2.9x | 10.9% | 14.0x |
| Moderna, Inc.MRNA | $20.5B | -7.3x | 2.4x | -32.6% | -7.5x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Zimmer Biomet Holdings, Inc.ZBH | $16.8B | 23.8x | 1.3x | 5.6% | 10.7x |
| Peer median | — | 23.8x | 2.7x | 7.9% | 13.2x |
Year-to-date ROI
INCY since 1 January, against earlier years.
Historical volatility
INCY's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 17.4% |
| FY2023 | 17.7% |
| FY2024 | 2.4% |
| FY2025 | 26.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $5.1B |
| Cost of revenueCost Of Revenue | $372.1M |
| Gross profitGross Profit | $4.8B |
| Operating expensesOperating Expense | $3.4B |
| Research and developmentResearch And Development | $2.1B |
| Selling, general and administrativeSelling General And Administration | $1.4B |
| Other operating expensesOther Operating Expenses | — |
| Total expensesTotal Expenses | $3.8B |
| Operating incomeOperating Income | $1.3B |
| Interest and other | |
| Pretax incomePretax Income | $1.7B |
| TaxTax Provision | $377.8M |
| Net incomeNet Income | $1.3B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $7.0B |
| Current assetsCurrent Assets | $5.0B |
| Non-current assetsTotal Non Current Assets | $1.9B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.8B |
| Current liabilitiesCurrent Liabilities | $1.5B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $275.3M |
| EquityTotal Equity Gross Minority Interest | $5.2B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.4B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.4B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.3B |
| Depreciation and amortisationDepreciation And Amortization | $93.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $93.3M |
| Stock-based compensationStock Based Compensation | $249.3M |
| Deferred taxDeferred Tax | $247.7M |
| Deferred income taxDeferred Income Tax | $247.7M |
| Operating gains and lossesOperating Gains Losses | -$21.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$21.3M |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | — |
| Asset impairmentAsset Impairment Charge | $76.3M |
| Change in working capitalChange In Working Capital | -$527.2M |
| Other non-cash itemsOther Non Cash Items | $8.7M |
| Investing cash flowInvesting Cash Flow | -$102.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$102.6M |
| Capital expenditureCapital Expenditure | -$83.9M |
| Capital expenditure (reported)Capital Expenditure Reported | -$58.9M |
| Purchase of investmentsPurchase Of Investment | -$303.4M |
| Sale of investmentsSale Of Investment | $284.6M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$18.7M |
| Purchase of intangiblesPurchase Of Intangibles | -$25.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$25.0M |
| Financing cash flowFinancing Cash Flow | $101.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $101.0M |
| Debt repaidRepayment Of Debt | -$4.5M |
| Net debt issuedNet Issuance Payments Of Debt | -$4.5M |
| Long-term debt repaidLong Term Debt Payments | -$4.5M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$4.5M |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $221.8M |
| Other financing chargesNet Other Financing Charges | -$116.2M |
| Change in cashChanges In Cash | $1.4B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -171.0% |
| Cash at the start of the yearBeginning Cash Position | $1.7B |
| Cash at the end of the yearEnd Cash Position | $3.1B |
| Free cash flowFree Cash Flow | $1.3B |
| Supplemental |
Learn while you research
Academy chapters picked for Incyte Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read